CD44 and breast cancer: Interestingly, an exposure of non-adherent human metastatic MDA-MB-231 and BCM2 breast cancer cells to three cycles of hypoxia and re-oxygenation has also been observed to be accompanied by an enrichment of the CD44+/CD24−/low/ESA+ BCSC fraction [79].